In idiopathic Parkinson's disease (IPD), disease-inherent degeneration of sleep regulation centers has been postulated, and rapid eye movement (REM) sleep behavior disorder has been identified as a forerunner syndrome.[@b1]--[@b4] With longer disease duration, polysomnography (PSG) evidenced progressive sleep "destructuring."[@b5] At an advanced stage of the disease, patients with IPD also have lower sleep efficiency and shorter REM stage than age-matched controls.[@b6] However, some of these findings have been collected in cohorts with variable disease duration and with preferential recruitment of the most disabled patients.[@b7] Thus, we lack objective PSG data on sleep quality and quantity in *early* motor stages of IPD.[@b7] The objective of the present study was to use PSG to search for REM sleep atonia in patients with early IPD, defined as a disease duration ≤3 years. Secondary objectives were to search for other objective sleep changes, to explore the impact of dopaminergic treatment on sleep quality and quantity, and, finally, to compare subjective sleep complaints with the PSG data.

Patients and Methods
====================

Within a *prospective* study on early nonmotor signs in patients with IPD, we recruited nondemented IPD patients.[@b8] Disease duration \<3 years was a strict inclusion criterion. Nondemented, healthy controls were recruited as nonconsanguineous family members or by the media. Controls underwent a brief medical check-up to exclude neurodegenerative or medical conditions, potentially endangering sleep quality. A 1-night PSG study was performed with a 16-channel montage, as previously described.[@b5],[@b8] To avoid a medication withdrawal effect, patients and controls were permitted to stay on their usual medications. Levodopa ([l]{.smallcaps}-dopa) equivalent daily doses (LEDD) were calculated by using the following formula: 100 mg [l]{.smallcaps}-dopa = 1 mg of pergolide = 10 mg bromocriptine = 3 mg of ropinirole = 1 mg of pramipexole.[@b9] Sleep stage classification was performed by dividing sleep into stage R (REM sleep), stage N 1 NREM 1) sleep, stage N 2 (NREM 2) sleep, and stage N 3 (NREM 3) sleep.[@b10] The following sleep parameters were evaluated: total sleep time; sleep latency; sleep efficiency; percentage of the different sleep stages; and indices per hour of sleep of apnea/hypopnea, periodic leg movements, awakenings, arousals. For these parameters, we used the definitions from another study published in this journal.[@b11] The percentage of muscle atonia during REM sleep was calculated according to Gagnon et al.[@b12] REM sleep was divided in epochs of 20 seconds. Loss of muscle atonia in an epoch was defined as the presence of ≥50% in that epoch of *any* chin electromyographic activity with an amplitude twice the amplitude measured during atonia and \>10 μV.[@b12] All participants fulfilled the Parkinson's disease sleepiness scale (PDSS).[@b13] To estimate subjective sleep quality, we added the scores obtained on questions 1, 2, 4, 14, and 15 of the PDSS and defined that score as the subjective sleep quality score (SSQS). Statistical analysis used χ[@b2] or Fisher exact tests for categorical data. Analyses of variance (ANOVA) were used on raw values with a Welch adjustment in case of nonhomogeneity of variances between groups, or on log-transformed values for continuous outcomes, as appropriate. Nonparametric tests, such as the Mann-Whitney test, were applied when normality was not verified. In this exploratory study, the percentage of REM sleep atonia was designated as the primary outcome variable; all other outcome variables were secondary. Before entering the study, all patients provided informed written consent, and the study had been approved by the National Ethical Committee for Research.

Results
=======

Demographic and Descriptive PSG Data in IPD Patients and Controls
-----------------------------------------------------------------

Demographic data are presented in [Table 1](#tbl1){ref-type="table"} and indicate that there was no significant difference between the patients with IPD and the control group. The PSG data are also shown in Table[1](#tbl1){ref-type="table"} and in [Figure 1](#fig01){ref-type="fig"}. The frequencies of different sleep dysfunction syndromes in both groups are presented in Supplemental Table 1. There was loss of muscle atonia during REM sleep in the patients with IPD (*P* \< 0.05). It is noteworthy that there were no personal accounts of potential previous REM sleep behavior disorder, and no participant exhibited acting out of dreams during PSG. Patients with IPD had the same amount of total sleep, the same percentage of sleep efficiency, and similar distribution of the different sleep stages. When comparing only those patients with IPD who were not on antidepressants versus those controls who were not on antidepressants, the absence of any difference was confirmed (data not shown). After omission of the nonsignificant interaction between age and diagnosis of IPD, there was an effect of age (*P* = 0.001; general linear model) on sleep efficiency. The negative correlation indicated decreasing sleep efficiency with increasing age, independent of IPD diagnosis (correlation coefficient \[*r*\] = −0.67; *P* \< 0.0001). The apnea/hypopnea index was correlated with body mass index in both patients with IPD and controls.

###### 

Demographic and polysomnographic data of 33 IPD patients and 37 age-matched controls

                                                             Mean ± SD or No. (%)                  
  ---------------------------------------------------------- ---------------------- -------------- ------------------------------------------
  Demographic data                                                                                 
   Age, y                                                    65.5 ± 11.6            66.7 ± 9.0     0.66^[a](#tf1-1){ref-type="table-fn"}^
   Sex: Men/women                                            12/21                  21/16          0.09
   Educational level, y                                      12.2 ± 3.7             12.6 ± 3.5     0.77^[b](#tf1-2){ref-type="table-fn"}^
   MMSE score                                                28.82 ± 1.7            28.78 ± 3.0    0.95^[b](#tf1-2){ref-type="table-fn"}^
   BMI, kg/m^2^                                              25.3 ± 3.9             27.0 ± 4.0     0.08^[b](#tf1-2){ref-type="table-fn"}^
   Hoehn-Yahr stage                                          2.0 ± 0.5              --             --
   PD duration, y                                            1.9 ± 1.3              --             --
   Levodopa dosage, mg                                       238.3 ± 331.5          --             --
   Dopamine agonists, mg^[c](#tf1-3){ref-type="table-fn"}^   1.0 ± 2.0              0.06 ± 0.3     \<0.01
   Antidepressants                                           8 (24)                 6 (16)         0.40
   Sedatives                                                 4 (12)                 5 (13)         0.86
   Total sleep time, min                                     308.8 ± 58.0           325.8 ± 63.5   0.24^[b](#tf1-2){ref-type="table-fn"}^
  Polysomnographic data                                                                            
   Total sleep time, min                                     308.8 ± 58.0           325.8 ± 63.5   0.24^[b](#tf1-2){ref-type="table-fn"}^
   Sleep latency, min                                        36.7 ± 27.3            36.3 ± 26.5    0.95^[a](#tf1-1){ref-type="table-fn"}^
   Sleep efficiency, %                                       72.1 ± 15.2            74.4 ± 12.9    0.49^[a](#tf1-1){ref-type="table-fn"}^
   NREM sleep stage 2, min                                   175.2 ± 47.0           176.4 ± 51.8   0.98^[d](#tf1-4){ref-type="table-fn"}^
   NREM sleep stage 2, %                                     43.4 ± 11.4            44.5 ± 13.3    0.61^[b](#tf1-2){ref-type="table-fn"}^
   NREM sleep stage 3, min                                   51.2 ± 45.7            61.9 ± 47.14   0.34^[a](#tf1-1){ref-type="table-fn"}^
   NREM sleep stage 3, %                                     13.6 ± 12.0            14.6 ± 9.2     0.69^[a](#tf1-1){ref-type="table-fn"}^
   REM sleep stage, min                                      43.0 ± 29.6            53.7 ± 25.9    0.09^[d](#tf1-4){ref-type="table-fn"}^
   REM sleep stage, %                                        11.1 ± 7.1             13.6 ± 7.1     0.15^[a](#tf1-1){ref-type="table-fn"}^
   Index of apnea/hypopnea/h                                 2.5 ± 4.9              2.1 ± 3.3      0.71^[a](#tf1-1){ref-type="table-fn"}^
   Index of periodic leg movements/h                         4.7 ± 14.9             5.8 ± 13.2     0.75^[a](#tf1-1){ref-type="table-fn"}^
   REM sleep muscle atonia, %                                79.9 ± 30.9            92.7 ± 22.4    0.0497^[a](#tf1-1){ref-type="table-fn"}^
   Awakenings/h                                              6.0 ± 4.0              4.5 ± 3.2      0.10^[a](#tf1-1){ref-type="table-fn"}^
   Arousals/h                                                7.8 ± 4.8              7.9 ± 6.7      0.94^[a](#tf1-1){ref-type="table-fn"}^

Welch analysis of variance.

Mann-Whitney test.

Expressed in pergolide equivalents, with 1 mg of pergolide = 10 mg bromocriptine = 3 mg of ropinirole = 1 mg of pramipexole.

Analysis of variance (log values).

SD, standard deviation; IPD, idiopathic Parkinson's disease; MMSE, Mini-Mental State Examination; BMI, body mass index; PD, Parkinson's disease; NREM, non-rapid eye movement; REM, rapid eye movement.

![Rapid eye movement (REM) sleep atonia is compared between 31 patients with idiopathic Parkinson's disease (IPD) and a group of 36 controls. Note that these numbers do not add up to the total numbers of patients and controls, because some individuals did not have any REM sleep).](mds0028-1443-f1){#fig01}

The Effect of Age and Dopaminergic Treatment on Sleep Quality in Patients With IPD
----------------------------------------------------------------------------------

In patients with IPD, age was linked to decreased percentages of total sleep time and REM sleep time and to an increased index of awakenings (see Supplemental Tables 2 and 3). [l]{.smallcaps}-dopa and dopamine agonists had a mild, but mostly statistically nonsignificant effect on total sleep time and sleep efficiency, with the former reducing these values and the latter increasing them (data not shown). However, when dopaminergic treatment was considered as a whole and expressed as the LEDD, no correlation was observed between the LEDD and the amount of NREM stage 2 or NREM stage 3 sleep (*r* = −0.04 \[*P* = 0.82\] and *r* = −0.27 \[*P* = 0.13\], respectively) (see Supplemental Table 4).

PDSS Questionnaire
------------------

Total scores on the PDSS were lower in the IPD patient group than in the control group (105.6 ± 22.0 vs 122.4 ± 15.4; *P* = 0.0005). In the patients with IPD, the SSQS score was not linked to sleep efficiency or with indices of arousals or awakenings (*r*~SSQS~ = 0.08, *r*~arousals~ = −0.22, and *r*~awakenings~ = −0.18).

Discussion
==========

The current study had an exploratory character, because we recruited a limited number of patients, and a power analysis was not performed. Evidently, larger scale studies are warranted to confirm these results. However, the actual sample size needed is unknown, because "the effect size between various sleep disorders and IPD has not been established."[@b7] This restriction also applies to the effect size required when comparing IPD patients with healthy controls. Despite these limitations, our study produced several novel results, which may be counterintuitive at first glance. These results can be summarized by the statement that, surprisingly, at an early stage in IPD (defined as disease duration \<3 years), objective sleep abnormalities still are very subtle. This statement is somehow in contradiction with Braak's model of an ascending degeneration in IPD. In this model, sleep-regulating centers, namely, the nucleus pedunculopontinus, locus coeruleus, and Raphé nuclei, are involved by the degenerative process ahead of the core motor syndrome. Thus, distinct clinical syndromes already should be present at an early stage. With this perspective, we could only confirm that some, but not all, patients with IPD have reduced percentages of muscle atonia during REM sleep.[@b3],[@b12] However, the mean reduction in REM sleep atonia for our whole group of patients with IPD was a robust finding, This reduction was less marked than that reported by Gagnon et al., who studied patients with a longer disease duration. The applied scoring method produced reliable results, as illustrated by identical mean scores for muscle atonia in our controls and in those reported by Gagnon et al.[@b12] Alternatively, consideration of phasic chin or limb muscle activity has been strongly advocated,[@b14] although it remains controversial whether specificity can be increased by adding up different methods.[@b15] In the future, computer-assisted, automated quantification of loss of atonia, possibly in more than 1 muscle, may be the method of choice.[@b16],[@b17] Negative ageing effects on sleep added up in patients with IPD more markedly than in age-matched controls, and a particularly significant interaction was observed between age and sleep efficiency.

PSG data on early stage PD are scarce, with only reports on small[@b18]--[@b20] and heterogeneous cohorts, because the results from patients with variable disease duration have often been presented together.[@b7] Patients with IPD in a middle disease stage have been compared with age-matched controls.[@b5],[@b21]--[@b23] The mean disease duration in the largest comparable study[@b21] was 6.4 years, in contrast to 1.9 years in the current study. In concordance with our study, the authors of that study did not observe increased numbers of arousals, indices of apnea/hypopnea, or periodic leg movements in patients with IPD. However, in contrast to our study, the patients who had IPD with longer disease duration had shorter total sleep time and lower sleep efficiency than the controls. Thus, it is possible that, at the end of the motor "honeymoon period", usually estimated to be 5 years long sleep "destructuring" becomes visible.[@b5] Unfortunately, a remarkable PSG study in terms of recruitment (greater than 400 patients) did not produce comparable results, because it included IPD inpatients who had an extremely wide range of disease duration and without a comparison group.[@b24]

We based our findings on a 1-night PSG registration, and participants were not acclimatized to the environment of a sleep laboratory. However, this restriction equally applied to the patients with IPD and the controls. We cannot exclude the possibility that the medical treatment somehow tempered the impact of the neurodegenerative process on sleep architecture, although dopaminergic treatment considered as a whole was without any major impact on sleep quality or quantity. We also cannot exclude the possibility that the use of sedatives and antidepressants, in both some patients and some controls, partially compensated for sleep fragmentation. Exclusive recruitment of de novo, drug-naive patients would have circumvented these potential elements of interference.

It has been puzzling to note that, in contrast to the rather reassuring PSG data, patients with early stage IPD had numerous subjective sleep complaints. A statistical link between the complaints and the objective sleep parameters could not be established. We are not aware of any other study that has compared subjective sleep complaints and PSG data at such an early stage in the disease. What are the possible causes for this discrepancy between subjective complaints and objective findings? It is possible that sleep questionnaires also register fatigue and exhaustion, which are not reflected by objective sleep data. It is also possible that in-depth PSG analysis or new evaluation tools, beyond routine PSG, would unmask subtle abnormalities that are undetectable using the current method. Promising methods have probed autonomic or sleep cycling regulation in sleep. Reduced heart rate variability as well as abnormalities in sleep microstructure have been reported.[@b18],[@b25]

In conclusion, this study confirms reduction of muscle atonia during REM sleep as a characteristic finding in early IPD, but does not (yet) show evidence any NREM sleep changes. Although sleep disturbances are considered to be an integral part of IPD, conventional PSG cannot yet objectify them at an early motor stage of the disease.

We thank Prof Dr. Mathias Maschke in Trier (Germany) and Drs. Stefan Beyenburg, Alexander Bisdorff, Pit Büchler, Dirk Droste, Marc Gleis, Bernd Wauschkuhn, all in Luxembourg, for the referral of patients for this study.

Author Roles
============

1\. Research Project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing the First Draft, B. Review and Critique.

N.J.D.: 1A, 1B, 2A, 2C, 3A

O.R.: 1C, 3B

V.P.: 1A, 1B, 1C, 2C, 3B

G.H.: 1B, 1C, 2C, 3B

M.V.: 1A, 2A, 2B, 3A, 3B

Financial Disclosures
=====================

Nico J. Diederich serves on the editorial board of *The Journal of Neurological Sciences* and has received travel grants from Abbott.

Supporting Information
======================

Additional Supporting Information may be found in the online version of this article.
